Perspective Therapeutics (NYSE:CATX) Now Covered by HC Wainwright

Stock analysts at HC Wainwright started coverage on shares of Perspective Therapeutics (NYSE:CATX) in a research note issued on Thursday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $10.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 275.94% from the stock’s previous close.

A number of other brokerages have also issued reports on CATX. Scotiabank started coverage on Perspective Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price objective for the company. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Royal Bank of Canada reissued an “outperform” rating and issued a $16.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, January 14th. Oppenheimer decreased their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. Finally, Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Perspective Therapeutics has a consensus rating of “Buy” and an average target price of $14.56.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $2.66 on Thursday. Perspective Therapeutics has a 12-month low of $2.32 and a 12-month high of $19.05. The business has a 50 day simple moving average of $3.17 and a 200 day simple moving average of $7.44.

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company lifted its position in shares of Perspective Therapeutics by 8.9% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after acquiring an additional 1,672 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Perspective Therapeutics by 5.8% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock valued at $783,000 after acquiring an additional 3,211 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Perspective Therapeutics by 7.4% during the 4th quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company’s stock valued at $163,000 after acquiring an additional 3,529 shares during the last quarter. US Bancorp DE lifted its position in shares of Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after acquiring an additional 3,866 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Perspective Therapeutics by 4.5% during the 4th quarter. Rhumbline Advisers now owns 94,992 shares of the company’s stock valued at $303,000 after acquiring an additional 4,075 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.